Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04214860
Title APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Aprea Therapeutics AB
Indications

acute myeloid leukemia

Therapies

APR-246 + Azacitidine + Venetoclax

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST